[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid-fatigue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid-fatigue":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100591454","phase-4-a-trial-of-shengmai-liquid-for-long-covid-fatigue-100591454",false,"NCT06980636","A Trial of Shengmai Liquid for Long COVID Fatigue.","Shengmai Liquid for Long COVID Fatigue: a Randomized Placebo-controlled Trial.","Shengmai LOFT","Inclusion Criteria:\n\n* Aged between 18 and 75 years;\n* Meet the above diagnostic criteria;\n* Meet the traditional Chinese medicine syndrome diagnostic criteria;\n* Consent and sign the informed consent form\n\nExclusion Criteria:\n\n* Currently in need of or expected to require high-flow oxygen therapy, positive pressure ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) and other advanced respiratory support measures;\n* Have a known history of active liver disease (excluding non-alcoholic fatty liver changes), including active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh class B or C liver function impairment, or acute liver failure. Liver function at screening shows any of the following: serum alanine aminotransferase (ALT) \\>3× the upper limit of normal (ULN); serum aspartate aminotransferase (AST) \\>3×ULN; serum bilirubin \\>2×ULN;\n* Undergoing dialysis treatment, or known to have moderate to severe renal impairment (i.e., an estimated glomerular filtration rate (eGFR) value calculated based on serum creatinine using the CKD-EPI formula ≤45 mL\u002Fmin\u002F1.73 m² within 6 months before screening);\n* Moderate to severe congestive heart failure within 6 months before screening (according to the New York Heart Association classification criteria, with cardiac function class III or IV), experienced a stroke, myocardial infarction, or coronary artery stent implantation; or have uncontrolled hypertension (defined as systolic blood pressure exceeding 160 mmHg or diastolic blood pressure exceeding 100 mmHg, with relevant records). Significant or clinically relevant electrocardiogram abnormalities, such as second-degree type II atrioventricular block, left bundle branch block, etc.;\n* Suffered from influenza A, influenza B, or other infectious diseases within 3 months before screening;\n* Have\u002Fever had severe neurological diseases (epilepsy, convulsions, or seizures) or mental illness, or have a family history of mental illness;\n* Pregnant or breastfeeding. Women who are breastfeeding or have a positive pregnancy test before taking the medication;\n* History of malignant tumors within 5 years before screening, with existing and progressing tumors, and patients who are expected to need treatment during the study period;\n* Have chronic fatigue syndrome or autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.);\n* Known allergy to any component of the study drug;\n* Diseases judged by the investigator to be unsuitable for participation in this study;\n* Taken traditional Chinese medicine containing Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, or Astragalus membranaceus within 2 weeks before screening;\n* Participating in other drug or medical device-related studies at the same time","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid. The main questions it aims to answer are:\n\n* Dose the Shengmai liquid will reduce the level of fatigue in the participants and reduce the fatigue scale score of the participants?\n* Dose the Shengmai liquid will reduce the level of anxiety and depression in the participants and improve the sleep quality and quality of life of the participants Researchers will compare Shengmai oral liquid to a placebo (a look-alike substance that contains no drug) to see if Shengmai liquid works to treat Long Covid fatigue.\n\nParticipants will:\n\n* Take Shengmai liquid or a placebo every day for 8 weeks.\n* Visit the clinic once every 4 weeks for check up and test. There are a total of two telephone follow-ups, one follow-up 15 days after the treatment starts and another follow-up 30 days after the treatment ends.\n* Participants' medication responses and scale scores will be recorded.",[28],"Long COVID Fatigue","RECRUITING","2026-02-05",{"date":32,"type":33},"2026-02-09","ACTUAL",{"date":35,"type":33},"2025-12-01",{"date":37,"type":22},"2026-11-30",{"name":39,"class":40},"Beijing University of Chinese Medicine","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100616956","whole-body-electrostimulation-for-functional-recovery-in-post-covid-syndrome-100616956","NCT07312357","Whole-Body Electrostimulation for Functional Recovery in Post-COVID Syndrome","Electrostimulation Suit as a Therapeutic Tool in Post-COVID Syndrome: Effects on Physical and Functional Status. A Randomized Controlled Trial","WB-EMS PostCOV","Inclusion Criteria:Adults aged 18 years or older.\n\nDiagnosis of post-COVID syndrome (long COVID), with persistent symptoms following SARS-CoV-2 infection.\n\nPresence of fatigue and\u002For functional limitations associated with post-COVID syndrome.\n\nAbility to understand the study procedures and provide written informed consent.\n\nAbility to participate in the intervention and assessments according to the study protocol.\n\n\\-\n\nExclusion Criteria:\n\nParticipation in other structured physical exercise or rehabilitation programs during the study period.\n\nPresence of severe cardiovascular disease or uncontrolled medical conditions that contraindicate physical activity or electrostimulation.\n\nNeurological disorders or severe neuromuscular diseases.\n\nUse of anabolic drugs or medications that may interfere with muscle function.\n\nPregnancy.\n\nEpilepsy.\n\nActive skin lesions or dermatological conditions in areas where electrodes are applied.\n\nRecent oncological surgery.\n\nAcute venous thrombosis.\n\nPresence of cardiac pacemakers or implanted electronic or conductive medical devices.\n\nAny clinical deterioration or condition that, in the opinion of the investigators, would make participation unsafe.\n\n\\-","70 Years",{"count":52,"type":22},30,[54],"NA","Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday activities, which can significantly impact quality of life and independence. At present, there is limited scientific evidence on effective rehabilitation strategies for this population.\n\nThe purpose of this study is to evaluate whether the use of a whole-body electrostimulation suit can improve fatigue, physical performance, and functional independence in people with post-COVID syndrome. Whole-body electrostimulation is a non-pharmacological technique that uses low-frequency electrical impulses to activate multiple muscle groups simultaneously and has shown potential benefits in other clinical populations.\n\nThis is a randomized, double-blind, controlled pilot clinical trial. Participants will be randomly assigned to either an experimental group, which will receive active whole-body electrostimulation during functional activities, or a control group, which will follow the same sessions using the electrostimulation suit with minimal stimulation (placebo condition). Neither participants nor outcome assessors will know which group each participant belongs to.\n\nThe intervention will consist of 12 supervised sessions conducted once per week. Outcomes will be assessed before and after the intervention, with an additional follow-up assessment three months later. The main outcomes include fatigue levels, functional capacity, physical performance, and independence in activities of daily living. Safety and tolerance to the intervention will be monitored throughout the study.\n\nThe results of this study may help to determine the feasibility and potential effectiveness of whole-body electrostimulation as a rehabilitation tool for people with post-COVID syndrome and provide preliminary data for future larger-scale clinical trials.",[57,58,28,59],"Post COVID Syndrome Long Covid","Post COVID Syndrome","Long Covid","NOT_YET_RECRUITING","2025-12-16",{"date":63,"type":33},"2025-12-31",{"date":65,"type":22},"2026-03",{"date":67,"type":22},"2026-12",{"name":69,"class":40},"Universidad Rey Juan Carlos",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":81,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100592359","observational-study-of-intranasal-ivig-in-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-patients-undergoing-medical-tourism-100592359","NCT06992401","Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism","An Observational Study Collecting Real-World Data on Intranasal IVIG Treatment in Long COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Immunodeficiency Engaged in International Medical Tourism","IVIG-LC","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection)\n* Laboratory-confirmed immunodeficiency, including one or more of the following:\n* Low serum IgG and\u002For IgA\n* Specific antibody deficiency\n* Low pneumonia titers\n* Elevated inflammatory markers (e.g., CRP, cytokines)\n* No active infections at the time of enrollment (bacterial, viral, or fungal)\n* Negative for Lyme disease and NMDAR antibodies\n* Willingness to provide informed consent for data collection and use\n\nExclusion Criteria:\n\n* Current or recent active infection (e.g., viral, bacterial, or fungal)\n* Use of immunosuppressive therapy within the last 3 months\n* Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded\n* Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded\n* Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded\n* Inability to comply with study assessments or procedures","65 Years",{"count":80,"type":22},50,"12 Weeks","OBSERVATIONAL","This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting.\n\nParticipants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation.\n\nThe goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.",[85,86,28,87,88,89],"Post-Acute Sequelae of SARS-CoV-2 Infection","Long COVID","Long COVID Syndrome","COVID 19 Associated Coagulopathy","COVID-19 Vaccination",[91,92,93,94,95,96,97,98,99,100,101,102],"Intranasal IVIG","Real-world data","Medical tourism","Long COVID fatigue","Cytokine panel","Immunoglobulin therapy","Brain fog","Chronic inflammation","Real-world evidence","Global health","Post-viral syndrome","Immune recovery","2025-11-24",{"date":105,"type":33},"2025-12-02",{"date":107,"type":22},"2026-08-01",{"date":109,"type":22},"2029-07-15",{"name":111,"class":40},"Tamara C Tamas",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100592360","exploring-the-therapeutic-effects-of-creatine-supplementation-for-long-covid-19-100592360","NCT06992414","Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19","Exploring Creatine Supplementation for Improved Exercise Capacity and Reduced Fatigue in Long COVID-19: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Experiencing symptoms at least 3 months after a COVID-19 diagnosis confirmed by positive polymerase chain reaction (PCR) test\n* Experiencing post-exertional malaise, as per the DePaul Symptom Questionnaire\n\nExclusion Criteria:\n\n* Allergy or intolerance to creatine monohydrate or maltodextrin\n* Supplemented with creatine in the past eight weeks\n* orthopaedic injury or condition that would prevent exercise testing\n* change in medication related to Long COVID symptom management in the past month.",{"count":120,"type":22},24,[54],"Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM",[28],[125,126,127,128],"creatine","post-exertional malaise","exercise","nutraceutical","2025-05-27",{"date":131,"type":33},"2025-05-31",{"date":133,"type":22},"2025-07-02",{"date":135,"type":22},"2026-10-31",{"name":137,"class":40},"University of Calgary"]